Apremilast for children with frequent mouth ulcers from Behçet’s disease
Treatments studied
Part of Eyes & vision, Genetic & congenital, Heart & circulation, Mouth & dental, Skin clinical trials.
This study tests apremilast to help reduce active, recurring mouth (oral) ulcers in children with Behçet’s disease. It may help if your child has had repeated mouth ulcers despite at least one non-biologic treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 2 and under 18 years old when the study starts
- A doctor has diagnosed Behçet’s disease using recognized criteria
- In the past 12 months, your child has had mouth ulcers at least 3 times
- At the screening visit and on Day 1, your child has at least 2 mouth ulcers
- Your child has tried at least one non-biologic Behçet’s treatment before (like steroid creams or pills)
- Your child does NOT have severe active Behçet’s organ or eye problems that need stronger immune-suppressing treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether apremilast can help reduce mouth ulcers in children who have Behçet’s disease or juvenile psoriatic arthritis. You may be considered if your child finished a main study and is under 18, and can safely continue treatment.
This study tests if ustekinumab or apremilast can help control Behçet's disease symptoms like mouth and genital ulcers, skin sores, and joint pain. It may be an option if standard treatments haven't worked well.
This Phase 3 trial tests whether apremilast can reduce severe, recurring mouth ulcers compared with an inactive placebo. It aims to improve ulcer frequency and pain while carefully checking safety.
This study tests a new pill called Hemay005 for adults with Behçet's disease who have at least two mouth sores that need treatment beyond creams or rinses. It aims to see if the drug safely reduces mouth ulcers.
This trial tests an experimental pill, HSK44459, for people with Behçet's disease who have frequent mouth ulcers. It aims to see if the drug can safely reduce ulcer episodes and improve symptoms.
This Phase 3 trial tests apremilast to treat active juvenile psoriatic arthritis (joint inflammation) in children and teens. You may be able to join if your child’s condition is active despite prior treatments or if they couldn’t tolerate them.
Hear when a new Behçet Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.